• Publications
  • Influence
International Union of Basic and Clinical Pharmacology. LXXXIII: Classification of Prostanoid Receptors, Updating 15 Years of Progress
It is now more than 15 years since the molecular structures of the major prostanoid receptors were elucidated. Since then, substantial progress has been achieved with respect to distribution andExpand
  • 322
  • 34
  • PDF
Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype.
A cDNA that when expressed has the binding and functional characteristics of the pharmacologically defined EP2 prostaglandin (PG) receptor [Cardiovasc. Drug Rev. 11:165-179 (1993)] has been clonedExpand
  • 379
  • 18
6-Isopropoxy-9-oxoxanthene-2-carboxylic acid (AH 6809), a human EP2 receptor antagonist.
On studying the interaction of various ligands with the pharmacologically defined, recombinant human EP2 receptor (Regan et al., Mol Pharmacol 46: 213-220, 1994), we discovered that the putative EP1Expand
  • 104
  • 15
Prostanoid receptor antagonists: development strategies and therapeutic applications
Identification of the primary products of cyclo‐oxygenase (COX)/prostaglandin synthase(s), which occurred between 1958 and 1976, was followed by a classification system for prostanoid receptors (DP,Expand
  • 134
  • 11
Finding of endocannabinoids in human eye tissues: implications for glaucoma.
Cannabinoid CB(1) receptors are involved in ocular physiology and may regulate intraocular pressure (IOP). However, endocannabinoid levels in human ocular tissues of cornea, iris, ciliary body,Expand
  • 88
  • 8
Cloning of a receptor for prostaglandin F2 alpha from the ovine corpus luteum.
A complementary DNA clone encoding a functional receptor for prostaglandin F2 alpha (PGF2 alpha) has been isolated from an ovine large luteal cell complementary DNA library (prepared from day 10Expand
  • 68
  • 6
EP1 Prostanoid Receptor Coupling to Gi/o Up-Regulates the Expression of Hypoxia-Inducible Factor-1α through Activation of a Phosphoinositide-3 Kinase Signaling Pathway
The EP1 prostanoid receptor is one of four subtypes whose cognate physiological ligand is prostaglandin-E2 (PGE2). It is in the family of G-protein-coupled receptors and is known to activate Ca2+Expand
  • 56
  • 6
Prostaglandin Ethanolamides (Prostamides): In Vitro Pharmacology and Metabolism
We investigated whether prostaglandin ethanolamides (prostamides) E2, F2α, and D2 exert some of their effects by 1) activating prostanoid receptors either per se or after conversion into theExpand
  • 138
  • 5
  • PDF
The pharmacology of bimatoprost (Lumigan).
Bimatoprost (Lumigan) is a pharmacologically unique and highly efficacious ocular hypotensive agent. It appears to mimic the activity of a newly discovered family of fatty acid amides, termedExpand
  • 198
  • 4
Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide.
PURPOSE To investigate long-term changes in the anterior segment of primate eyes treated for one year with different prostaglandin agonists and a prostamide. The results were compared with thoseExpand
  • 106
  • 4
  • PDF